Activating mutations in the kinase domain of the epidermal growth factor receptor (EGFR) drive the growth of 10–30% of non-small cell lung cancers (NSCLCs), the leading cause of cancer mortality worldwide with a five-year survival rate of 23% [1]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.